Literature DB >> 17008366

Use of routinely collected amniotic fluid for whole-genome expression analysis of polygenic disorders.

Gyula Richárd Nagy1, Balázs Gyõrffy, Orsolya Galamb, Béla Molnár, Bálint Nagy, Zoltán Papp.   

Abstract

BACKGROUND: Neural tube defects related to polygenic disorders are the second most common birth defects in the world, but no molecular biologic tests are available to analyze the genes involved in the pathomechanism of these disorders. We explored the use of routinely collected amniotic fluid to characterize the differential gene expression profiles of polygenic disorders.
METHODS: We used oligonucleotide microarrays to analyze amniotic fluid samples obtained from pregnant women carrying fetuses with neural tube defects diagnosed during ultrasound examination. The control samples were obtained from pregnant women who underwent routine genetic amniocentesis because of advanced maternal age (>35 years). We also investigated specific folate-related genes because maternal periconceptional folic acid supplementation has been found to have a protective effect with respect to neural tube defects.
RESULTS: Fetal mRNA from amniocytes was successfully isolated, amplified, labeled, and hybridized to whole-genome transcript arrays. We detected differential gene expression profiles between cases and controls. Highlighted genes such as SLA, LST1, and BENE might be important in the development of neural tube defects. None of the specific folate-related genes were in the top 100 associated transcripts.
CONCLUSIONS: This pilot study demonstrated that a routinely collected amount of amniotic fluid (as small as 6 mL) can provide sufficient RNA to successfully hybridize to expression arrays. Analysis of the differences in fetal gene expressions might help us decipher the complex genetic background of polygenic disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17008366     DOI: 10.1373/clinchem.2006.074971

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  6 in total

1.  Standardization of amniotic fluid leptin levels and utility in maternal overweight and fetal undergrowth.

Authors:  M Scott-Finley; J G Woo; M Habli; O Ramos-Gonzales; J F Cnota; Y Wang; B D Kamath-Rayne; A C Hinton; W J Polzin; T M Crombleholme; R B Hinton
Journal:  J Perinatol       Date:  2015-04-30       Impact factor: 2.521

2.  Threshold for neural tube defect risk by accumulated singleton loss-of-function variants.

Authors:  Zhongzhong Chen; Yunping Lei; Yufang Zheng; Vanessa Aguiar-Pulido; M Elizabeth Ross; Rui Peng; Li Jin; Ting Zhang; Richard H Finnell; Hongyan Wang
Journal:  Cell Res       Date:  2018-07-05       Impact factor: 25.617

3.  Key Modules and Hub Genes Identified by Coexpression Network Analysis for Revealing Novel Biomarkers for Spina Bifida.

Authors:  Zijian Li; Juan Feng; Zhengwei Yuan
Journal:  Front Genet       Date:  2020-12-02       Impact factor: 4.599

4.  Systems biology analysis of human genomes points to key pathways conferring spina bifida risk.

Authors:  Vanessa Aguiar-Pulido; Paul Wolujewicz; Alexander Martinez-Fundichely; Eran Elhaik; Gaurav Thareja; Alice Abdel Aleem; Nader Chalhoub; Tawny Cuykendall; Jamel Al-Zamer; Yunping Lei; Haitham El-Bashir; James M Musser; Abdulla Al-Kaabi; Gary M Shaw; Ekta Khurana; Karsten Suhre; Christopher E Mason; Olivier Elemento; Richard H Finnell; M Elizabeth Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2021-12-21       Impact factor: 11.205

5.  An upstream open reading frame regulates LST1 expression during monocyte differentiation.

Authors:  Christian Schiller; Carina Nowak; Kalliope N Diakopoulos; Ulrich H Weidle; Elisabeth H Weiss
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

6.  Lst1 deficiency has a minor impact on course and outcome of the host response to influenza A H1N1 infections in mice.

Authors:  Sarah R Leist; Heike Kollmus; Bastian Hatesuer; Ruth L O Lambertz; Klaus Schughart
Journal:  Virol J       Date:  2016-01-27       Impact factor: 4.099

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.